Clinical Features in Parkinson’s Disease Patients with Hyperechogenicity in Substantia Nigra: A Cross-Sectional Study

References

• Olson K, Bade A, Schutt C, et al. Manganese-enhanced magnetic resonance imaging for detection of vasoactive intestinal peptide receptor 2 agonist therapy in a model of Parkinson’s disease. Neurotherapeutics. 2016;13(3):635–646. doi:10.1007/s13311-016-0449-z
   Web of Science ®Google Scholar
• Okawa M, Miwa H, Kajimoto Y, et al. Transcranial sonography of the substantia nigra in Japanese patients with Parkinson’s disease or atypical parkinsonism: clinical potential and limitations. Intern Med. 2007;46(18):1527–1531. doi:10.2169/internalmedicine.46.0271
   Web of Science ®Google Scholar
• Mei YL, Yang J, Wu ZR, Yang Y, Xu YM. Transcranial sonography of the substantia nigra for the differential diagnosis of Parkinson’s disease and other movement disorders: a meta-analysis. Parkinsons Dis. 2021;2021:8891874. doi:10.1155/2021/8891874
   Web of Science ®Google Scholar
• Heinzel S, Aho V, Suenkel U, et al. Gut microbiome signatures of risk and prodromal markers of Parkinson disease. Ann Neurol. 2021;90(3):E1–E12. doi:10.1002/ana.26128
   PubMed Web of Science ®Google Scholar
• Yu SY, Cao C, Zuo L, et al. Clinical features and dysfunctions of iron metabolism in Parkinson disease patients with hyper echogenicity in substantia nigra: a cross-sectional study. BMC Neurol. 2018;18(1):9. doi:10.1186/s12883-018-1016-5
   PubMed Web of Science ®Google Scholar
• Toomsoo T, Liepelt-Scarfone I, Berg D, et al. Effect of age on substantia nigra hyper-echogenicity in Parkinson’s disease patients and healthy controls. Ultrasound Med Biol. 2019;45(1):122–128. doi:10.1016/j.ultrasmedbio.2018.09.018
   Web of Science ®Google Scholar
• Behnke S, Runkel A, Kassar H, et al. Long-term course of substantia nigra hyperechogenicity in Parkinson’s disease. Mov Disord. 2013;28(4):455–459. doi:10.1002/mds.25193
   Web of Science ®Google Scholar
• Lobsien E, Schreiner S, Plotkin M, Kupsch A, Schreiber S, Doepp F. No correlation of substantia nigra echogenicity and nigrostriatal degradation in Parkinson’s disease. Mov Disord. 2012;27(3):450–453. doi:10.1002/mds.24070
   Web of Science ®Google Scholar
• Shin C, Hahn S, Park B, et al. Predictors of the placebo response in clinical trials on Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord. 2016;29:83–89. doi:10.1016/j.parkreldis.2016.05.019
   Web of Science ®Google Scholar
• Lord S, Galna B, Yarnall A, Coleman S, Burn D, Rochester L. Predicting first fall in newly diagnosed Parkinson’s disease: insights from a fall-naïve cohort. Mov Disord. 2016;31(12):1829–1836. doi:10.1002/mds.26742
   PubMed Web of Science ®Google Scholar
• Curtze C, Nutt J, Carlson-Kuhta P, Mancini M, Horak F. Objective gait and balance impairments relate to balance confidence and perceived mobility in people with Parkinson disease. Phys Ther. 2016;96(11):1734–1743. doi:10.2522/ptj.20150662
   Web of Science ®Google Scholar
• Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–1601. doi:10.1002/mds.26424
   PubMed Web of Science ®Google Scholar
• Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol. 2008;7(11):1044–1055. doi:10.1016/S1474-4422(08)70239-4
   Web of Science ®Google Scholar
• Tao S, Zhang X, Cai H, Lv Z, Hu C, Xie H. Gait based biometric personal authentication by using MEMS inertial sensors. J Ambient Intell Humaniz Comput. 2018;9(5):1705–1712. doi:10.1007/s12652-018-0880-6
   Web of Science ®Google Scholar
• Mancini M, King L, Salarian A, et al. Mobility lab to assess balance and gait with synchronized body-worn sensors. J Bioeng Biomed Sci. 2011;Suppl 1:007. doi:10.4172/2155-9538.S1-007
   PubMedGoogle Scholar
• Galna B, Lord S, Rochester L. Is gait variability reliable in older adults and Parkinson’s disease? Towards an optimal testing protocol. Gait Posture. 2013;37(4):580–585. doi:10.1016/j.gaitpost.2012.09.025
   PubMed Web of Science ®Google Scholar
• Bryant M, Rintala D, Hou J, Collins R, Protas E. Gait variability in Parkinson’s disease: levodopa and walking direction. Acta Neurol Scand. 2016;134(1):83–86. doi:10.1111/ane.12505
   Web of Science ®Google Scholar
• Patterson K, Gage W, Brooks D, Black S, McIlroy W. Evaluation of gait symmetry after stroke: a comparison of current methods and recommendations for standardization. Gait Posture. 2010;31(2):241–246. doi:10.1016/j.gaitpost.2009.10.014
   PubMed Web of Science ®Google Scholar
• Zhang M, Artan N, Gu H, et al. Gait study of Parkinson’s disease subjects using haptic cues with a motorized walker. Sensors. 2018;18(10).
   Web of Science ®Google Scholar
• Walter U, Skoloudík D, Berg D. Transcranial sonography findings related to non-motor features of Parkinson’s disease. J Neurol Sci. 2010;289(1–2):123–127. doi:10.1016/j.jns.2009.08.027
   Web of Science ®Google Scholar
• Zhou HY, Sun Q, Tan YY, et al. Substantia nigra echogenicity correlated with clinical features of Parkinson’s disease. Parkinsonism Relat Disord. 2016;24:28–33. doi:10.1016/j.parkreldis.2016.01.021
   Web of Science ®Google Scholar
• Li T, Shi J, Qin B, et al. Increased substantia nigra echogenicity correlated with visual hallucinations in Parkinson’s disease: a Chinese population-based study. Neurol Sci. 2020;41(3):661–667. doi:10.1007/s10072-019-04110-z
   Web of Science ®Google Scholar
• Del Toro Perez C, Amaya Pascasio L, Arjona Padillo A, et al. Neurosonological findings related to non-motor features of Parkinson’s disease: a systematic review. Brain Sci. 2021;11(6):776. doi:10.3390/brainsci11060776
   Web of Science ®Google Scholar
• Zhang S, Tao K, Wang J, Duan Y, Wang B, Liu X. Substantia nigra hyperechogenicity reflects the progression of dopaminergic neurodegeneration in 6-OHDA rat model of Parkinson’s disease. Front Cell Neurosci. 2020;14:216. doi:10.3389/fncel.2020.00216
   Web of Science ®Google Scholar
• Harrison M, Wylie S, Frysinger R, et al. UPDRS activity of daily living score as a marker of Parkinson’s disease progression. Mov Disord. 2009;24(2):224–230. doi:10.1002/mds.22335
   PubMed Web of Science ®Google Scholar
• Zhou HY, Huang P, Sun Q, et al. Substantia nigra echogenicity associated with clinical subtypes of Parkinson’s disease. J Parkinsons Dis. 2018;8(2):333–340. doi:10.3233/JPD-171264
   Google Scholar
• Goetz C, Tilley B, Shaftman S, et al. Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–2170. doi:10.1002/mds.22340
   PubMed Web of Science ®Google Scholar
• Ward R, Zucca F, Duyn J, Crichton R, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13(10):1045–1060. doi:10.1016/S1474-4422(14)70117-6
   PubMed Web of Science ®Google Scholar
• Berg D, Godau J, Riederer P, Gerlach M, Arzberger T. Microglia activation is related to substantia nigra echogenicity. J Neural Transm. 2010;117(11):1287–1292. doi:10.1007/s00702-010-0504-6
   Web of Science ®Google Scholar
• Hausdorff J, Cudkowicz M, Firtion R, Wei J, Goldberger A. Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson’s disease and Huntington’s disease. Mov Disord. 1998;13(3):428–437. doi:10.1002/mds.870130310
   PubMed Web of Science ®Google Scholar
• Callisaya M, Blizzard L, Schmidt M, et al. Gait, gait variability and the risk of multiple incident falls in older people: a population-based study. Age Ageing. 2011;40(4):481–487. doi:10.1093/ageing/afr055
   PubMed Web of Science ®Google Scholar
• Schlachetzki JCM, Barth J, Marxreiter F, et al. Wearable sensors objectively measure gait parameters in Parkinson’s disease. PLoS One. 2017;12(10):e0183989. doi:10.1371/journal.pone.0183989
   PubMed Web of Science ®Google Scholar
• Yogev G, Plotnik M, Peretz C, Giladi N, Hausdorff J. Gait asymmetry in patients with Parkinson’s disease and elderly fallers: when does the bilateral coordination of gait require attention? Exper Brain Res. 2007;177(3):336–346. doi:10.1007/s00221-006-0676-3
   Web of Science ®Google Scholar
• Plotnik M, Giladi N, Balash Y, Peretz C, Hausdorff J. Is freezing of gait in Parkinson’s disease related to asymmetric motor function? Ann Neurol. 2005;57(5):656–663. doi:10.1002/ana.20452
   Web of Science ®Google Scholar
• Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson’s disease. Mov Disorders. 2005;20(3):383–385. doi:10.1002/mds.20311
   PubMed Web of Science ®Google Scholar
• Postuma R, Gagnon J, Montplaisir J. Clinical prediction of Parkinson’s disease: planning for the age of neuroprotection. J Neurol Neurosurg Psychiatry. 2010;81(9):1008–1013. doi:10.1136/jnnp.2009.174748
   PubMed Web of Science ®Google Scholar
• Bártová P, Skoloudík D, Ressner P, Langová K, Herzig R, Kanovsky P. Correlation between substantia nigra features detected by sonography and Parkinson disease symptoms. J Ultrasound Med. 2010;29(1):37–42. doi:10.7863/jum.2010.29.1.37
   Web of Science ®Google Scholar
• Chen W, Tan Y, Hu Y, et al. Combination of olfactory test and substantia nigra transcranial sonopraphy in the differential diagnosis of Parkinson’s disease: a pilot study from China. Transl Neurodegener. 2012;1(1):25. doi:10.1186/2047-9158-1-25
   PubMedGoogle Scholar
• Li D, Zhang L, Hu Y, et al. Transcranial sonography of the substantia nigra and its correlation with DAT-SPECT in the diagnosis of Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(8):923–928.
   Web of Science ®Google Scholar
• Liu P, Li X, Li F, Ou-Yang Q, Zhang H, Feng T. The predictive value of transcranial sonography in clinically diagnosed patients with early stage Parkinson’s disease: comparison with DAT PET scans. Neurosci Lett. 2014;582:99–103. doi:10.1016/j.neulet.2014.08.053
   Web of Science ®Google Scholar
• Tsai C, Wu R, Huang Y, Chen L, Yip P, Jeng J. Transcranial color-coded sonography helps differentiation between idiopathic Parkinson’s disease and vascular parkinsonism. J Neurol. 2007;254(4):501–507. doi:10.1007/s00415-006-0403-9
   Web of Science ®Google Scholar
• Weise D, Lorenz R, Schliesser M, Schirbel A, Reiners K, Classen J. Substantia nigra echogenicity: a structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson’s disease. Mov Disord. 2009;24(11):1669–1675. doi:10.1002/mds.22665
   Web of Science ®Google Scholar